Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 06, 2018

Pembrolizumab vs Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic HNSCC

The Lancet


Additional Info

The Lancet
Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study
Lancet 2018 Nov 30;[EPub Ahead of Print], EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, A Soria, JP Machiels, N Mach, R Mehra, B Burtness, P Zhang, J Cheng, RF Swaby, KJ Harrington

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading